Alnylam Pharmaceuticals
ALNY
#626
Rank
A$47.51 B
Marketcap
$370.14
Share price
-1.87%
Change (1 day)
17.37%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): A$0.11 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings (TTM) are A$0.10 B. In 2023 the company made an earning of -A$0.47 B an increase over its 2022 earnings that were of -A$1.46 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) A$0.11 B-124.76%
2023 -A$0.47 B-67.84%
2022 -A$1.46 B36.93%
2021 -A$1.07 B-8.04%
2020 -A$1.16 B-15.66%
2019 -A$1.38 B12.23%
2018 -A$1.23 B62.91%
2017 -A$0.76 B17.78%
2016 -A$0.64 B43.44%
2015 -A$0.45 B60.69%
2014 -A$0.28 B98.2%
2013 -A$0.14 B
2011 -A$82.23 M27.48%
2010 -A$64.5 M-10.92%
2009 -A$72.41 M95.77%
2008 -A$36.99 M
2006 -A$59.25 M-9.13%
2005 -A$65.21 M34.74%
2004 -A$48.4 M36.79%
2003 -A$35.38 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-A$0.79 B-861.40%๐Ÿ‡บ๐Ÿ‡ธ USA
A$6.88 B 6,544.07%๐Ÿ‡บ๐Ÿ‡ธ USA
A$93.32 M-9.88%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$0.37 B-454.33%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$46.3 M-144.71%๐Ÿ‡บ๐Ÿ‡ธ USA
A$16.34 B 15,686.04%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
A$10.12 B 9,676.31%๐Ÿ‡ซ๐Ÿ‡ท France
A$1.24 B 1,097.82%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel